title: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
abstract: BACKGROUND
  Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures.
  
  
  OBJECTIVE
  To determine whether once-weekly oral bisphosphonate can prevent bone loss and reduce bone turnover in men receiving ADT.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled, partial crossover trial. First-year, preplanned analysis of a 2-group, parallel-design phase.
  
  
  METHODS
  University medical center.
  
  
  METHODS
  112 men with nonmetastatic prostate cancer receiving ADT.
  
  
  METHODS
  Alendronate, 70 mg once weekly, or placebo. All patients received calcium and vitamin D supplementation.
  
  
  METHODS
  Bone mineral density of the spine and hip and markers of bone resorption and formation.
  
  
  RESULTS
  At baseline, 39% of men had osteoporosis and 52% had low bone mass. In men treated with alendronate, bone mineral density increased over 1 year by 3.7% (95% CI, 2.8% to 4.6%; P < 0.001) at the spine and 1.6% (CI, 0.4% to 2.8%; P = 0.008) at the femoral neck. Men in the placebo group had losses of 1.4% (CI, -2.7% to - 0.03%; P = 0.045) at the spine and 0.7% (CI, -1.5% to 0.01%; P = 0.081) at the femoral neck. At 12 months, the difference between the 2 groups was 5.1 percentage points (CI, 3.5 to 6.7 percentage points; P < 0.001) at the spine and was 2.3 percentage points (CI, 1.0 to 3.7 percentage points; P < 0.001) at the femoral neck. Bone turnover statistically significantly decreased with active therapy compared with placebo. The groups did not differ in adverse events.
  
  
  CONCLUSIONS
  The study was short (1 year) and was not powered to detect differences in the frequency of fractures.
  
  
  CONCLUSIONS
  Bone loss that occurred with ADT was prevented and improved with once-weekly oral alendronate. Because most men have low bone mass or osteoporosis, physicians should assess their patients' bone density and provide preventive and therapeutic measures as appropriate. ClinicalTrials.gov registration number: NCT00048841.
authors: University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors: Susan L
authors: SL
authors: Greenspan
authors: Joel B
authors: JB
authors: Nelson
authors: Donald L
authors: DL
authors: Trump
authors: Neil M
authors: NM
authors: Resnick
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D000726:Androgen Antagonists / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006615:Hip; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D013131:Spine / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D019386:Alendronate